Treatment with tocilizumab for corticosteroid-resistant forms of autoimmune orbitopathy in Graves' disease
Abstract
The article describes the experience of tocilizumab using in three patients with severe autoimmune orbitopathy who did not respond to treatment with pulse corticosteroid therapy. The only alternative for these patients was surgery. Our goal was to evaluate the effectiveness and safety of treatment with tocilizumab for this pathology.
About the Authors
T. V. Mokhort
Белорусский государственный медицинский университет
Belarus
Belarus
K. A. Polovinkina
Минский городской клинический эндокринологический центр
Belarus
Belarus
V. N. Shishko
Минский городской клинический эндокринологический центр
Belarus
Belarus
A. G. Mokhort
Белорусский государственный медицинский университет
Belarus
Belarus
A. V. Yurenya
Минский городской клинический эндокринологический центр
Belarus
Belarus
N. M. Likhorad
31-я городская клиническая больница
Belarus
Belarus
A. K. Dyagileva
31-я городская клиническая больница
Belarus
Belarus
References
1. Bartalena L., Baldeschi L., Boboridis K. et al. European Group on Graves´ Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves´ Orbitopathy Guidelines for the Management of Graves´ Orbitopathy. Eur. Thyroid J. 2016; 5 (1): 9—26.
2. Kahaly G. J., Bartalena L., Hegedus L. et al. European Thyroid Association guideline for the management of Graves´ hyperthyroidism. Eur. Thyroid J. 2018; 7 (4): 167—86.
3. Bartalena L., Kahaly G. J., Baldeschi L. et al. EUGOGO. The 2021 European Group on Graves´ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves´ orbitopathy. Eur. J. Endocrinol. 2021; 185 (4): G43— G67. doi: 10.1530/EJE-21-0479.
4. Burch H. B., Perros P., Bednarczuk T. et al. Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. Eur. Thyroid J. 2022; 11 (6): e220189.
5. Mourits M. P., Prummel M. F., Wiersinga W. M., Koornneef L. Clinical activity score as a guide in the management of patients with Graves´ ophthalmopathy. Clin. Endocrinol. (Oxf). 1997; 47 (1): 9—14.
6. Perez-Moreiras J. V., Varela-Agra M., Prada-Sanchez M. C., PradaRamallal G. Steroid-resistant Graves´ orbitopathy treated with tocilizumab in real-world clinical practice: a 9- year single-center experience. J. Clin. Med. 2021; 10 (4):706. doi. org/10.3390/jcm10040706. Perez-Moreiras J. V., Alvarez-Lopez A., Gomez E. C. Treatment of active corticosteroid-resistant graves´ orbitopathy. Ophthalmic Plast. Reconstr. Surg. 2014; 30 (2): 162—7.
7. Perez-Moreiras J. V., Gomez-Reino J. J., Maneiro J. R. et al Efficacy tocilizumab in patients with moderate-to-severe corticosteroidresistant graves orbitopathy: A randomized clinical trial. Am. J. Ophthalmol. 2018; 195: 181—90.
8. Copperman T., Idowu O. O., Kersten R. C., Vagefi M. R. Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery. Ophthalmic Plast. Reconstr. Surg. 2019; 35: e64—e66.
9. Silkiss R. Z., Paap M. K., Roelofs K. A. et al Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab. Can. J. Ophthalmol. 2021; 56: 66—70.
10. Wiersinga W. M., Prummel M. F., Terwee C. B. Effects of Graves´ ophthalmopathy on quality of life. J. Endocrinol. Invest. 2004; 27: 259—64.
Review
For citations:
Mokhort T.V., Polovinkina K.A., Shishko V.N., Mokhort A.G., Yurenya A.V., Likhorad N.M., Dyagileva A.K. Treatment with tocilizumab for corticosteroid-resistant forms of autoimmune orbitopathy in Graves' disease. Healthcare. 2024;(4):46-52. (In Russ.)
Views:
14
Email this article 